Publications by authors named "William Freimuth"

Claim this Profile
N
New craniodental materials of Falcarius utahensis (Theropoda: Therizinosauria) reveal patterns of intraspecific variation and cranial evolution in early coelurosaurians.
William J Freimuth, Lindsay E Zanno

Anat Rec (Hoboken)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.
Herbert Struemper, Milena Kurtinecz, Lisa Edwards, William W Freimuth, David A Roth

Lupus Sci Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early mammalian social behaviour revealed by multituberculates from a dinosaur nesting site.
Lucas N Weaver, David J Varricchio, Eric J Sargis, Meng Chen, William J Freimuth

Nat Ecol Evol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring.
Jeremy D Gale, Jeff Jensen, Gabe Berman, William Freimuth, Gang Li

Plast Reconstr Surg Glob Open· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
Richard Furie, Michelle A Petri, Vibeke Strand, Dafna D Gladman, Z John Zhong, William W Freimuth

Lupus Sci Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
Vibeke Strand, Roger A Levy, Ricard Cervera, Michelle A Petri, Helen Birch, William W Freimuth

Ann Rheum Dis· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ellen M Ginzler, Daniel J Wallace, Joan T Merrill, Richard A Furie, William Stohl, William W Freimuth

J Rheumatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.
Michelle A Petri, Ronald F van Vollenhoven, Jill Buyon, Roger A Levy, Sandra V Navarra, William W Freimuth

Arthritis Rheumatol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.
Wendy W Cai, Michele Fiscella, Cecil Chen, Z John Zhong, William W Freimuth

Clin Pharmacol Drug Dev· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Michelle A Petri, Ronald F van Vollenhoven, Jill Buyon, Roger A Levy, Sandra V Navarra, William W Freimuth

Arthritis Rheum· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
William Stohl, Joan T Merrill, James D McKay, Jeffrey R Lisse, Z John Zhong, William W Freimuth

J Rheumatol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Susan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, Richard Furie, Dafna Gladman, William Freimuth

Ann Rheum Dis· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.
Gene D Morse, Margaret A Fischl, Mark J Shelton, Steve R Cox, Leslie Thompson, William W Freimuth

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.
Gene D Morse, Susan E Cohn, Mark J Shelton, Carol Greisberger, Steven R Cox, William W Freimuth

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
Joan T Merrill, Ellen M Ginzler, Daniel J Wallace, James D McKay, Jeffrey R Lisse, William W Freimuth

Arthritis Rheum· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
Ronald F van Vollenhoven, Michelle A Petri, Ricard Cervera, David A Roth, Beulah N Ji, William Freimuth

Ann Rheum Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
W Winn Chatham, Daniel J Wallace, William Stohl, Kevin M Latinis, Susan Manzi, William W Freimuth

J Rheumatol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
William Stohl, Falk Hiepe, Kevin M Latinis, Mathew Thomas, Morton A Scheinberg, William W Freimuth

Arthritis Rheum· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J Wallace, William Freimuth

Arthritis Rheum· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, William Freimuth

Lancet· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Annett M Jacobi, Weiqing Huang, Tao Wang, William Freimuth, Inaki Sanz

Arthritis Rheum· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Daniel J Wallace, William Stohl, Richard A Furie, Jeffrey R Lisse, James D McKay, William W Freimuth

Arthritis Rheum· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel evidence-based systemic lupus erythematosus responder index.
Richard A Furie, Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William W Freimuth

Arthritis Rheum· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Richard Furie, William Stohl, Ellen M Ginzler, Michael Becker, Nilamadhab Mishra, William Freimuth

Arthritis Res Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Michelle Petri, William Stohl, Winn Chatham, W Joseph McCune, Marc Chevrier, William Freimuth

Arthritis Rheum· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis